2022
DOI: 10.1080/14756366.2022.2041627
|View full text |Cite
|
Sign up to set email alerts
|

Development of naringenin-O-alkylamine derivatives as multifunctional agents for the treatment of Alzheimer’s disease

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
4
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 8 publications
(4 citation statements)
references
References 35 publications
0
4
0
Order By: Relevance
“…The blood–brain barrier (BBB) permeability and ADMET were important parameters for evaluating anti‐AD drugs (Yang, Zhou, et al., 2022). In this work, the computer‐assisted evaluation methods were used.…”
Section: Resultsmentioning
confidence: 99%
“…The blood–brain barrier (BBB) permeability and ADMET were important parameters for evaluating anti‐AD drugs (Yang, Zhou, et al., 2022). In this work, the computer‐assisted evaluation methods were used.…”
Section: Resultsmentioning
confidence: 99%
“…Moreover, 5f and 7k could cross the BBB, significantly inhibited self-induced Aβ 1 - 42 aggregation and huAChE-Aβ 1–40 aggregation as well as selective metal chelators, and remarkably inhibited Cu 2+ -induced Aβ 1–42 aggregation. In addition, the in vivo study reported that compound 5f significantly improved spatial learning and memory in scopolamine-induced AD mice [ 246 ]. Naringenin analog 5-hydroxy-2-(4-hydroxyphenyl)-4-oxochroman-7-yl piperidine-1-carboxylate, showed anti-AD effects by suppressing BuChE and AChE activity and scavenging OH and displayed better inhibitory potency on self-induced Aβ 1 - 42 aggregation.…”
Section: Neuroprotective Mechanisms Of Dietary Small Molecules Analog...mentioning
confidence: 99%
“…The cholinergic hypothesis states that the degeneration of cholinergic neurons and the associated loss of cholinergic neurotransmission (e.g., acetylcholine) in the cerebral cortex are responsible for the deterioration of cognitive function observed in the brains of patients with AD [ 96 ]. The brains of patients with AD exhibit reduced activity of acetylcholinesterase (AChE) and acetylcholinesterase (ChAT), as well as a significant deficiency in acetylcholine.…”
Section: Mechanisms Of the Neuroprotective Effects Of Walnut Peptidesmentioning
confidence: 99%